Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis chronic obstructive pulmonary disease~* Relatively stable airway obstruction with post FEV1 \>=30 and \< 80% predicted normal and post FEV1/ FVC \< 70%~* Male or female patients, 40 years of age or more~* Smoking history more than 10 pack years~Exclusion criteria:~* Significant diseases other than COPD~* History of asthma~* COPD exacerbation in previous 3 months~* Completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program.~* Pregnant or nursing women~* Patients unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium + olodaterol low dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium + olodaterol high dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- placebo (Type: PLACEBO_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).